Press Releases

Occlutech Appoints Thomas J. Bogenschütz as Chairman of the Board

Published on: July 9, 2025

Occlutech® Announces Commercial Cases of Occlutech ASD Occluder Device Implantation in the U.S.

Published on: August 28, 2024

Occlutech® Announces FDA Approval of its Occlutech® ASD Occluder and Occlutech® Pistol Pusher, a Minimally Invasive Cardiac Device and Delivery System to Treat Atrial Septal Defects

Published on: January 8, 2024

Occlutech Year-end report 2022 – Significant uptick in sales growth as transformation processes are reaching an end

Published on: May 3, 2023

Occlutech receives subscription commitment of bonds amounting to EUR 40 million in nominal value under a total frame of EUR 75 million to finance US expansion and growth

Published on: April 5, 2023

Occlutech announces first patient enrollment in important US pivotal study for the Atrial Flow Regulator (FROST-HF)

Published on: March 13, 2023

Occlutech announces change to the Executive Management Team

Published on: February 1, 2023

Occlutech continues its progress in US FDA study OCCLUFLEX – enrolls first patient in Europe

Published on: January 31, 2023

Occlutech announces new member to the Executive Management Team by appointing Chief Medical Officer

Published on: November 1, 2022

Occlutech announces new members to the Executive Management Team – appoints Chief Commercial Officer and Vice President Global Business Development & Marketing

Published on: September 6, 2022

Load More Press Releases

Subscribe